 So good afternoon everybody. My name is Bokki Han, Director of Center for Synom Science at the Korea National Institute of Health. First of all, I would like to thank Dr. Eric Green and Professor... Zinsberg, right? And Dr. Manuel Leo for actually giving me an opportunity to speak in this meeting of global leaders of genomic medicine. So today I would like to talk about Korea in the Korea Synomic Medicine and its plan and infrastructures. This is contents of my presentation. Korean government ministries planned cooperative genome research project in two years ago. This shows the overview of multi-multi-ministry synomic research project of Korea. The project called Synome Technology to Business Translation Program. This project will be conducted from 2014 to 2021 with a funding of $500. Maybe the amount of funding can change. So there is three types of objectives, human, non-human, and then in first. So for the human genome implementation of synomic medicine is the representative goal of this project. This slide represents the functions of different ministries that are involved in genome research project. The MHWMA or MOF is the name of ministries and the major area of their work is human, agriculture, modern life, basic research and industrialization. These are the upcoming research topics that are funded by each ministries. And the joint project could be funded by several ministries. So the research topics funded by Ministry of Health and Welfare are the steps that lead to the implementation of synomic medicine. This slide shows the cooperative links between ministries. These research topics link to each other and support project development. The results of basic research can be used for application research and once the outcome of application research is approved, the results are available for industrial application. Ministry of Health and Welfare supports synomics for personalized medicine and translational research and the production of Korean synomic information. These all project or research topics will converse and will be integrated to realize our ultimate goal of genome research to business system translation. The Ministry of Health and Welfare supports research topics in order to realize synomic medicine for next generation. The vision is promotion of public health and personalized medicine. The mission is to develop prevention, diagnosis and treatment by using collected synomic resources and informatics. The main project funded by Ministry of Health and Welfare can be categorized into five topics including ethics and legal social implications. This slide shows the detailed project within each topic. The results of these projects will be integrated for synomic information and joint projects will involve cooperation with other ministries such as the Ministry of Science or Trade. This slide shows the conceptual diagram of a project funded by Ministry of Health and Welfare, disease mechanism, translational research and disease genomics and genomic resources are connected in a cycle. Synomic information from these researches will be used for the future researches such as predicting diseases or reducing complications, etc. These are new projects that will be conducted in this year in 2014 with a funding of $10 million. Research on clinical genomics will be launched. ELSI Center is studied. The production of Korean genomic information based cohort will continue. In addition, it is undergoing preparation for the Registrating Genomic Research Act and the Technical Roadmap for Precision Medicine. Dr. Seo Jung-seon is PI of the Technical Roadmap Project. So now I will explain about genomic medicine infrastructures of Center for Genome Science at Korea NIH. Center for Genome Science consists of four different divisions. Division of Epidemiology and Health Index conducts cohort studies. The rest are division of biomedical informatics, division of structural and functional genomics, and biobank. As the only National Health Institute in Korea, Center for Genome Science has established genomic resources by producing large scale of genomics and epidemiological data as well as biobank specimens. These genomic resources are provided to other researchers, especially those who are supported by Ministry of Health and Welfare. In short, at Korea NIH, we are conducting projects that provide infrastructures for genomic researches. Our mission is to provide infrastructures by producing genomic and epidemiological data and sharing. Furthermore, we conduct GWAS and prospective cohort studies to find out genetic and environmental and gene-environmental interactive factors associated with Korean traits. Current main project of Center for Genome Science are three Korea Genome and Epidemiological Studies courses, biobank project, genome analysis project. Cougis project has collected large scale of epidemiological data and biospecimens such as urine and blood, DNA, serum and plasma and so on through cohort studies. The main age group of cohort is from 40 to 69 and about 250 participants are recorded. So Cougis has more than 240,000 epidemiological individual data. There are three different types of cohort, community-based, health-examining and gene-environmental interaction cohort. On the base of the whole genome analysis of Cougis samples, we conducted several GWAS including anthropometric traits and metabolic traits. Our researchers have published 13 articles in major journals. So I would like to talk about Korea Biobank project. National Biobank and 17 regional biobanks are connected through Korea Biobank Network, KBN. KBN provides sample quality control guideline and education for standardization and harmonization of biobank. This shows Korea Biobanks. National Biobank Korea is located in Korea NIH and regional biobanks are located in university hospitals. As a control tower, National Biobank developed Cougis technique and manages the samples and accelerates the active distribution of biospecimen. This slide shows the biospecimen collection from 600,000 participants. The samples of national biobanks are collected from cohort studies and disease prevention research such as Korea enhanced studies. The samples of regional biobanks are collected from patients. This shows the distribution of human biospecimens. Total 913 research projects have used biobank resources. This shows snapshot of MBK, I apologize for Korean. The KBN is a portal site for Korea Biobank project. In this portal site, researchers can get certain information on biospecimen and any other relevant information. So here is the other project, Korean genome analysis project. Through this project, we have produced genome-wide data. Our research objectives are to discover genetic factors and construct reference information infrastructure such as Korea reference genome by whole genome sequencing data. Dr. Jo Sung-beom is in charge of Korea genome reference project. Korea reference epigenome project are also conducted. We plan to produce 50 epigenome maps until 2017 with a budget of $10 million. Produced data will be shared with the IHEC and international scientific community. So in sum up, this shows perspectives and issues. To realize our mission, we need to promote data sharing and set up long-term plan for genome research. And we have faced obstacles in funding and in legal ethical issues. These issues remain to be solved. Maybe today or in this meeting, we can talk about these issues and we cooperate with each other. I think these obstacles can be overcome by looking into the various needs of stakeholders and assuring stable funding and also dealing with legal ethical issues related to privacy protection laws. In Korea, we have ethical laws. So thank you for attention. Dr. Han, you mentioned Korea's specific traits and it was sort of interesting. I mean it got me thinking that in some ways these might be, I hate to call them experiments of nature, but might be things that you could learn about your country but also might give insights into many other things. So for example, the diabetes patients have, they are not so, the BMI of these diabetes patients is very low. I think people have diabetes, so maybe there is some specific or genetic traits or so. Question about the consent for your biobanks. Since you have a federated system with various biobanks feeding the overall enterprise, have you had difficulties harmonizing consent? From the outset, a single consent that is applying to all biobanks, if you could just comment on that. So as I told you, we have in Korea ethical law. So in this law states the form of and the contents of informed contents form. So we use this form of informed consent. What is the structure of electronic records in the medical system in Korea? I think maybe Dr. So can explain more about that because it is the medical record. I think it is quite good in Korea. Does it use a say SNOMED with a Korean translation or is it a separate semantic system? The SNOMED, right. But it is not interoperable with, is it interoperable with Western systems? Thank you.